Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up


Regan M. M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., ...More

LANCET ONCOLOGY, vol.12, no.12, pp.1101-1108, 2011 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 12
  • Publication Date: 2011
  • Doi Number: 10.1016/s1470-2045(11)70270-4
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1101-1108
  • Istanbul University Affiliated: No

Abstract

Background Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up.